New hope for B-ALL: targeted drug added to chemo shows promise
NCT ID NCT05453500
First seen Jan 09, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This study tests adding a targeted drug called tafasitamab to a standard chemotherapy regimen for adults newly diagnosed with a fast-growing blood cancer called B-ALL. The goal is to see if the combination can clear more cancer cells from the bone marrow after just one cycle of treatment. The trial involves 32 adults who are not good candidates for more intensive pediatric-style treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.